ATE266646T1 - Phenanthryl-piperazinyl-dicarbonsäure als selective nmda-rezeptor modulierende mittel - Google Patents

Phenanthryl-piperazinyl-dicarbonsäure als selective nmda-rezeptor modulierende mittel

Info

Publication number
ATE266646T1
ATE266646T1 AT00986451T AT00986451T ATE266646T1 AT E266646 T1 ATE266646 T1 AT E266646T1 AT 00986451 T AT00986451 T AT 00986451T AT 00986451 T AT00986451 T AT 00986451T AT E266646 T1 ATE266646 T1 AT E266646T1
Authority
AT
Austria
Prior art keywords
nmda receptor
receptor modulating
phenanthryl
piperazinyl
selective nmda
Prior art date
Application number
AT00986451T
Other languages
English (en)
Inventor
Daniel T Monaghan
David E Jane
Heong Wai Tse
Original Assignee
Univ Bristol
Univ Nebraska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bristol, Univ Nebraska filed Critical Univ Bristol
Application granted granted Critical
Publication of ATE266646T1 publication Critical patent/ATE266646T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9466—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00986451T 1999-12-16 2000-12-18 Phenanthryl-piperazinyl-dicarbonsäure als selective nmda-rezeptor modulierende mittel ATE266646T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9929582.6A GB9929582D0 (en) 1999-12-16 1999-12-16 Chemical compounds
PCT/US2000/034137 WO2001044205A2 (en) 1999-12-16 2000-12-18 Phenanthryl piperazinyl dicarboxylic acids as selective nmda receptor modulating agents

Publications (1)

Publication Number Publication Date
ATE266646T1 true ATE266646T1 (de) 2004-05-15

Family

ID=10866322

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00986451T ATE266646T1 (de) 1999-12-16 2000-12-18 Phenanthryl-piperazinyl-dicarbonsäure als selective nmda-rezeptor modulierende mittel

Country Status (7)

Country Link
EP (1) EP1244638B1 (de)
AT (1) ATE266646T1 (de)
AU (1) AU783141B2 (de)
CA (1) CA2395290A1 (de)
DE (1) DE60010755T2 (de)
GB (1) GB9929582D0 (de)
WO (1) WO2001044205A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003609B2 (en) * 2004-03-30 2011-08-23 The Hospital For Sick Children Method for ameliorating pain by modification of NMDA receptors through inhibition of Src
US7425540B2 (en) * 2004-03-30 2008-09-16 The Hospital For Sick Children Method for modification of NMDA receptors through inhibition of Src
WO2014173900A1 (en) * 2013-04-22 2014-10-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of epileptic seizures

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1248531A (en) * 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
WO1994024284A1 (en) * 1993-04-20 1994-10-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Human n-methyl-d-aspartate receptor subunits, nucleic acids encoding same and uses therefor

Also Published As

Publication number Publication date
EP1244638B1 (de) 2004-05-12
GB9929582D0 (en) 2000-02-09
WO2001044205A3 (en) 2002-02-21
WO2001044205A2 (en) 2001-06-21
CA2395290A1 (en) 2001-06-21
AU2268901A (en) 2001-06-25
DE60010755D1 (en) 2004-06-17
AU783141B2 (en) 2005-09-29
EP1244638A2 (de) 2002-10-02
DE60010755T2 (de) 2005-09-01

Similar Documents

Publication Publication Date Title
KR890011601A (ko) (사이클로알킬아미노)메틸렌비스(포스폰산)및 활성성분으로서 이를 함유한 의약
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
DE60107395D1 (de) 1,5-benzothiazepine und ihre verwendungs als hypolipidämika
SE9903760D0 (sv) New compounds
DE69327438D1 (de) Therapeutische Mittel für die Parkinsonsche Krankheit
AU515774B2 (en) Benzopyran derivatives
HK1013289A1 (en) Naphthalene derivatives as prostaglandin 12 agonists
DK0663902T3 (da) 25-carboxylsyrederivater i vitamin D-rækken, farmaceutiske præparater indeholdende disse derivater samt deres anvendelse ti
ES2187025T3 (es) Nuevos agentes quelantes de hierro (iii) activos via oral.
ES2055235T3 (es) Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation.
ATE266646T1 (de) Phenanthryl-piperazinyl-dicarbonsäure als selective nmda-rezeptor modulierende mittel
MX9804828A (es) Benzotiazolona etanaminas biologicamente activas.
AU4250200A (en) Ppar-(gamma) agonists as agents for the treatment of type ii diabetes
RS50033B (sr) Derivati etansulfonil-piperidina
NO985202L (no) Anti-heliobacter pylori-preparater inneholdende 1-metylcarbapenemderivater
DK0420224T3 (da) Anthihepatopatisk middel
SE7904543L (sv) Nya joniska bensen-polyjodidderivat for anvendning som kontrastmedel vid rontgenbehandling
ATE104313T1 (de) Neue 9-g(a)-hydroxy-3-oxo-4,24(25)-stigmastadien26-s|urederivate,verfahren zur herstellung und heilmittel daraus.
ATE206431T1 (de) Antifungal fusacandine
IT1289979B1 (it) 5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari
BR9611805A (pt) Derivados de amino álcool processos para a sua produção e agentes farmacêuticos contendo estes compostos
NO20004685L (no) Nye forbindelser
EA200001157A2 (ru) Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
KR970042513A (ko) 히스티딘 유도체, 이의 제조방법 및 이를 함유한 약제학적 조성물
CA2238710A1 (en) New amino alcohol derivatives, processes for their production and pharmaceutical agents containing these compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties